TG Therapeutics Shares Rise Above $40 Amid Analyst Reviews
Recently, shares of TG Therapeutics Inc (Symbol: TGTX) reached a price of $40.30, surpassing the average analyst 12-month target price of $40.00. When a stock meets its analysts’ target, they usually have two choices: downgrade based on valuation or adjust the target price upwards. Such reactions may also depend on the company’s underlying business developments. If positive trends are emerging, an increase in the target price may be warranted.
Within the Zacks coverage universe, there are seven distinct analyst targets contributing to TG Therapeutics Inc.’s average price assessment. However, this average is merely a mathematical compilation. Notably, some analysts maintain lower targets, with one suggesting a price of $11.00, while another sets a considerably higher target of $55.00, resulting in a standard deviation of $16.852.
The purpose of examining the average target price for TGTX is to leverage a “wisdom of crowds” approach. This combines the insights of various analysts rather than relying on a single expert’s opinion. With TGTX exceeding the average target price of $40.00 per share, investors are encouraged to reassess the company. The key question remains: does this signify just a step towards an even higher target, or has the valuation stretched enough to consider taking profits?
| Recent TGTX Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong Buy ratings: | 6 | 6 | 6 | 6 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 1 | 1 | 1 | 1 |
| Sell ratings: | 1 | 1 | 1 | 1 |
| Strong Sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.63 | 1.63 | 1.63 | 1.63 |
The average rating in the table ranges from 1 to 5, where 1 is a Strong Buy and 5 is a Strong Sell. The data utilized in this article is sourced from Zacks Investment Research via Quandl.com.
The views and opinions expressed herein are solely those of the author and do not reflect those of any affiliations.
